On the stock market since 2002, it operates in the world of health and science. It has 200 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 28% a year over the last 4 years. Red columns mark years that ended in a loss.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
The net profit margin is 51% — still a thick cushion, though costs have been eating into it lately.
Over the last 3 years, sales grew about 44% a year on average.
There is $114.3M in the vault; even if every debt were paid off, $55.5M would remain.
The price action doesn’t yet back an upward turn. Council score: 0/10.
On our five-subject report card, BDSI sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: BDSI is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.